The clinical-stage pharmaceutical company plans to use the funds for phase III clinical trials of its lead product candidates.
Both companies involved in the deal are based in Israel.
ARMO Biosciences Inc plans to raise $86.25m through an initial public offering (IPO) of shares and has filed a registration statement with the US Securities and Exchange Commission for the same.
The late-stage immuno-oncology company plans to use proceeds towards the development of its AM0010 product candidate for the treatment of PDAC, and for other general corporate purposes.
CymaBay Therapeutics plans to issue securities in a public offering to raise $200m.
The US-based biopharmaceutical company plans to issue common stock, preferred stock, debt securities and warrants in one or more offerings to raise the funds.
CymaBay will use funds for working capital and other general corporate purposes.
Recro Pharma plans to raise $40m through a public offering of shares.
The US-based specialty pharmaceutical company plans to use proceeds to fund phase IIIB clinical trials of IV meloxicam and for general corporate purposes.
Saniona AB has raised Skr72m ($8.72m) through the private placement of convertible bonds.
Switzerland-based financial services firm Nice & Green SA will subscribe to the placement.
The Denmark-based biotech company plans to use the proceeds to finance operations and investments in its internally developed drug programme in the medium term.